Tadalafil is widely known as a tablet medicine, but an FDA-approved oral suspension also exists in the United States. TADLIQ contains tadalafil at 20 mg per 5 mL and belongs to the pulmonary arterial hypertension, or PAH, product context rather than the Cialis ED/BPH product framework.
An oral suspension is a different finished dosage form from a tablet. Tadalafil is dispersed within a liquid formulation and the medicine is measured by volume, which makes concentration and formulation-specific handling important when interpreting the product.
This page focuses on tadalafil oral suspension as a pharmaceutical formulation: what 20 mg/5 mL means, why the bottle is shaken, how a suspension differs conceptually from tablets and how the PAH context fits. Full brand-specific information belongs on TADLIQ, while the direct formulation comparison belongs on Tadalafil Tablets vs Oral Suspension.
TADLIQ provides the current FDA-approved U.S. example of tadalafil in oral-suspension form. The important formulation facts are its active ingredient, liquid dosage form, concentration, oral route and PAH labeling.
These features define the suspension context without requiring the complete product monograph.
| Formulation Feature | Tadalafil Oral Suspension Context |
|---|---|
| Active ingredient | Tadalafil |
| Product example | TADLIQ |
| Dosage form | Oral suspension |
| Concentration | 20 mg/5 mL |
| Equivalent concentration | 4 mg/mL |
| Route | Oral |
| Labeled context | Pulmonary arterial hypertension, WHO Group 1 |
| Key handling step | Shake well for 30 seconds before measuring |
| Deeper product detail | TADLIQ |
A suspension is a liquid dosage form in which drug material is dispersed through a liquid vehicle rather than necessarily being completely dissolved. TADLIQ uses this formulation approach to deliver tadalafil orally.
That distinction has practical consequences. The product is measured as a liquid volume and requires mixing before measurement, whereas tadalafil tablets are supplied as solid dosage units.
| Term | Meaning |
|---|---|
| Oral | Administered by mouth |
| Suspension | Liquid dosage form containing dispersed drug material |
| Concentration | Amount of tadalafil contained in a defined liquid volume |
| TADLIQ | Specific FDA-approved tadalafil oral-suspension product |
The expression 20 mg/5 mL means that each 5 mL of suspension contains 20 mg of tadalafil. The same concentration can also be expressed as 4 mg/mL.
This notation differs from a tablet strength because a tablet states a fixed amount per solid unit, while a liquid product expresses drug amount relative to volume. Concentration describes the product; it is not by itself an individualized dosing recommendation.
| Expression | Meaning |
|---|---|
| 20 mg/5 mL | 20 mg tadalafil in 5 mL of suspension |
| 4 mg/mL | Equivalent concentration per milliliter |
| 5 mL | Contains 20 mg tadalafil at the labeled concentration |
| 10 mL | Contains 40 mg tadalafil at the labeled concentration |
Concentration answers how much tadalafil exists in each unit of liquid volume. Dose and regimen answer how much is administered and how treatment is scheduled within a particular clinical context.
That distinction matters because the suspension concentration remains 20 mg/5 mL even when product-specific dosing considerations change. Regimen-level questions belong on Tadalafil Dosage and the disease-specific framework on Tadalafil for Pulmonary Hypertension.
| Concept | Question It Answers |
|---|---|
| Concentration | How much tadalafil is present per volume? |
| Measured volume | How much suspension is being measured? |
| Dose | How much tadalafil is administered? |
| Regimen | How is treatment scheduled? |
TADLIQ is a specific branded tadalafil oral-suspension product rather than a generic term for every liquid preparation containing tadalafil. Current U.S. labeling places it in the treatment of pulmonary arterial hypertension, WHO Group 1, to improve exercise ability.
The dosage-form name and brand name therefore describe different things: tadalafil oral suspension identifies the formulation category, while TADLIQ identifies a particular finished product. The dedicated TADLIQ product page owns deeper brand-specific detail.
| Statement | Accurate? |
|---|---|
| TADLIQ contains tadalafil | Yes |
| TADLIQ is an oral suspension | Yes |
| TADLIQ is labeled in the PAH context | Yes |
| TADLIQ means every liquid tadalafil preparation | No |
| TADLIQ is simply liquid Cialis for ED | No |
Current U.S. labeling indicates TADLIQ for pulmonary arterial hypertension, WHO Group 1, to improve exercise ability. ED and BPH are not listed as TADLIQ indications.
That distinction prevents the phrase 'liquid tadalafil' from being interpreted as a liquid version of every tadalafil treatment framework. The broader indication map is covered on Tadalafil Uses.
| Clinical Context | TADLIQ Label |
|---|---|
| PAH, WHO Group 1 | Labeled indication |
| Treatment objective | Improve exercise ability |
| ED | Not a labeled TADLIQ indication |
| BPH | Not a labeled TADLIQ indication |
Current TADLIQ labeling instructs users to shake the bottle well for 30 seconds before measuring the suspension. The instruction is formulation-specific and helps redistribute the suspended material before a liquid volume is measured.
The need to shake belongs to the suspension rather than to tadalafil as an active molecule. Tablet products do not acquire this handling requirement simply because they contain the same drug.
| Handling Point | Current Suspension Context |
|---|---|
| Shake before measurement | Yes |
| Label-specified duration | 30 seconds |
| Why it matters | Redistributes the suspension before measuring |
| Universal rule for all tadalafil products? | No |
Both dosage forms can deliver the same active molecule by mouth, but the finished products are constructed and measured differently. The suspension uses a liquid volume and concentration, while a tablet provides tadalafil in a solid unit.
The table below provides only the formulation-level distinction required to understand the suspension. A full head-to-head comparison belongs on Tadalafil Tablets vs Oral Suspension.
| Feature | Oral Suspension | Tablet |
|---|---|---|
| Active ingredient | Tadalafil | Tadalafil |
| Physical form | Liquid suspension | Solid tablet |
| Drug quantity expressed as | mg per volume | mg per tablet |
| How product is measured | Liquid volume | Tablet unit |
| Suspension mixing step | Yes for TADLIQ | Not applicable |
| Same finished formulation | No | No |
Current labeling describes TADLIQ as a white to off-white, opaque suspension with peppermint flavor. These characteristics describe the finished liquid formulation and should not be generalized to tadalafil as a molecule or to tablet products.
Appearance is useful for describing the formulation, but actual product identification still depends on the labeled container and prescription information rather than color or flavor alone.
| Characteristic | Current TADLIQ Description |
|---|---|
| Color | White to off-white |
| Physical appearance | Opaque suspension |
| Flavor | Peppermint |
| Active drug | Tadalafil |
The finished product contains tadalafil plus formulation-specific excipients that support the liquid vehicle, suspension properties, stability and palatability. Current labeling lists ingredients including glycerin, polysorbate 80, xanthan gum, sodium benzoate, sucralose, citrate components, purified water, peppermint flavor and a simethicone emulsion.
Those ingredients belong to this particular formulation and should not be assumed to occur in tadalafil tablets or other liquid preparations. Exact ingredient questions should be checked against the label for the actual supplied product.
| Formulation Layer | Examples |
|---|---|
| Active ingredient | Tadalafil |
| Suspension-related excipients | Xanthan gum, polysorbate 80, glycerin and other product-specific components |
| Flavor / sweetening components | Peppermint flavor and sucralose |
| Vehicle | Purified water with formulation-specific excipients |
FDA's quality review describes tadalafil oral suspension under NDA 214522 as a new dosage form and formulation developed through the 505(b)(2) pathway. The application relied in part on FDA's previous findings for Adcirca tablets and also included supporting in-vivo bioavailability information.
For formulation purposes, the key point is that the active tadalafil and oral route can remain the same while dosage form, formulation and composition differ. That regulatory finding supports treating the suspension as a distinct finished product rather than simply calling it a tablet converted into liquid.
| FDA Review Point | Suspension Context |
|---|---|
| Application | NDA 214522 |
| Pathway | 505(b)(2) |
| Listed drug used in the application | Adcirca tadalafil tablets |
| Active ingredient | Tadalafil |
| Dosage form / formulation | Different from the listed tablet product |
| Supporting pharmacokinetic evidence | In-vivo bioavailability data |
FDA's quality assessment describes the suspension as a formulation intended to provide an administration option for patients who may have difficulty swallowing tablets. The benefit is therefore related to dosage-form administration rather than a different tadalafil mechanism.
A liquid format also changes how the medicine is measured, making concentration and volume important product concepts. It does not automatically transfer ED or BPH indications from other tadalafil products.
| Question | Formulation Interpretation |
|---|---|
| Different active molecule? | No |
| Different dosage form? | Yes |
| Measured by liquid volume? | Yes |
| Potential administration advantage | Can provide an alternative for patients who have difficulty swallowing tablets |
| Automatically carries Cialis indications? | No |
Current labeling permits TADLIQ to be taken with or without food. FDA's clinical-pharmacology review found modest food-related increases in tadalafil exposure with the suspension that were not considered clinically significant.
This food information is useful as an administration property of the formulation, but the deeper pharmacokinetic interpretation belongs on Tadalafil Food Effects.
| Food Question | Current Context |
|---|---|
| Administration with food | Permitted |
| Administration without food | Permitted |
| Food changes the dosage form? | No |
| Detailed PK interpretation | Tadalafil Food Effects |
TADLIQ is a defined FDA-approved formulation with a specified concentration, composition and regulatory application. A separately compounded tadalafil liquid may use a different recipe, concentration, preparation process or stability framework and is not automatically the same finished product.
The informal phrase 'liquid tadalafil' therefore needs product context. The actual label or prescription should identify what formulation has been supplied.
| Term | Meaning |
|---|---|
| TADLIQ | Specific FDA-approved tadalafil oral suspension |
| Tadalafil oral suspension | Dosage-form description |
| Compounded tadalafil liquid | Separately prepared product that is not automatically TADLIQ |
| "Liquid tadalafil" | Informal description requiring product clarification |
Changing from a tablet to an oral suspension does not create a different tadalafil molecule. The active drug remains tadalafil and retains its underlying PDE5-inhibiting pharmacology.
What changes is the finished dosage form, formulation and product label. Mechanism questions belong on How Tadalafil Works, while the overall dosage-form map is covered on Tadalafil Formulations.
| Layer | Suspension Relationship |
|---|---|
| Active molecule | Tadalafil |
| Drug class | PDE5 inhibitor |
| Physical dosage form | Different from a tablet |
| Inactive ingredients | Formulation-specific |
| Product labeling | Product-specific |
Because the suspension still contains tadalafil, the active drug's contraindication and interaction framework remains relevant. The formulation itself does not eliminate concerns involving nitrates, guanylate-cyclase stimulators or overlapping PDE5-inhibitor therapy.
Those safety topics are intentionally not reproduced here. See Tadalafil Contraindications and Tadalafil Drug Interactions for the detailed safety framework.
| Formulation Question | Answer |
|---|---|
| Does liquid form change the active drug? | No |
| Do core tadalafil interaction principles remain relevant? | Yes |
| Is this page the full safety guide? | No |
Most confusion comes from treating concentration, dose, dosage form and product identity as though they were interchangeable. A suspension can contain the same active molecule as a tablet while still requiring different measurement and handling.
The TADLIQ name also should not be generalized to every possible tadalafil-containing liquid.
| Misunderstanding | More Accurate Interpretation |
|---|---|
| "Tadalafil only exists as tablets" | No; an FDA-approved oral suspension also exists |
| "20 mg/5 mL means 20 mg in 1 mL" | No; the concentration is 4 mg/mL |
| "TADLIQ is liquid Cialis for ED" | No; TADLIQ is a separate PAH-labeled tadalafil product |
| "A suspension is simply a dissolved tablet" | No; it is a separately formulated liquid dosage form |
| "TADLIQ and Adcirca are the same finished product" | No; they share tadalafil and PAH context but use different dosage forms |
| "Any tadalafil liquid is TADLIQ" | No; TADLIQ is a specific FDA-approved formulation |
| "The liquid form changes tadalafil into another active drug" | No; the active molecule remains tadalafil |
Yes. TADLIQ is an FDA-approved tadalafil oral suspension in the U.S. pulmonary arterial hypertension product context.
TADLIQ contains 20 mg tadalafil per 5 mL of suspension, equivalent to 4 mg/mL.
It means that 5 mL of the suspension contains 20 mg of tadalafil. The equivalent concentration is 4 mg per milliliter.
TADLIQ is labeled as an oral suspension. It should not be described as an oral solution.
Current U.S. labeling indicates TADLIQ for pulmonary arterial hypertension, WHO Group 1, to improve exercise ability.
No. ED is not listed as a TADLIQ indication in the current U.S. label.
No. BPH is not listed as an indication in the current TADLIQ label.
No. Both contain tadalafil, but Cialis is a tablet product in the ED/BPH context while TADLIQ is an oral suspension labeled for PAH.
No. Both contain tadalafil and belong to the PAH context, but Adcirca is a tablet product while TADLIQ is an oral suspension with a different formulation.
TADLIQ is a suspension, and current labeling instructs users to shake it well for 30 seconds before measuring. The step helps redistribute the suspended formulation before a liquid volume is measured.
Current labeling instructs users to shake the bottle well for 30 seconds before measuring the suspension.
Current labeling describes it as a white to off-white, opaque oral suspension with peppermint flavor.
Yes. Current labeling permits TADLIQ to be taken with or without food.
Yes. Tadalafil is the active ingredient in both the suspension and tadalafil tablet products. The dosage form, formulation and inactive ingredients differ.
Five milliliters of the suspension and a 20 mg tablet can each contain 20 mg of tadalafil, but they remain different dosage forms and finished products. Matching milligrams alone does not make products identical.
No automatic substitution should be inferred merely from equal tadalafil amounts. Product identity, indication, dosage form and prescribing context still matter.
No. TADLIQ is a specific FDA-approved formulation, while other liquid preparations should be identified by their own product or compounding information.
FDA's quality review describes the suspension as an alternative oral dosage form intended in part for patients who may have difficulty swallowing tablets.